Advanced Osmotic Drug Delivery of Glipizide: Formulation Optimization and Release Kinetics of Controlled Porosity Tablets
Abstract
Background: Diabetes mellitus is a long-term illness that needs sustained therapy to keep glycemic control intact. Glipizide is an effective second-generation sulfonylurea but has a short half-life, thus requiring prolonged dosing that compromises compliance in patients. Controlled-release drug delivery systems provide an answer by delivering constant drug levels over a long duration of time. Osmotic controlled-release tablets, specifically, facilitate drug delivery irrespective of gastrointestinal motility and pH, which makes them suitable for drugs such as Glipizide.
Objective: Innovative drug delivery systems have advanced oral controlled-release systems, offering benefits over immediate-release forms by maintaining consistent drug concentration, reducing dosing frequency, and improving patient adherence.
Methods: Tablet cores were prepared via wet granulation and coated with cellulose acetate and potassium chloride for semipermeable membranes. Pre-compression parameters of the granules indicated excellent flow properties, while post-compression parameters such as weight variation, hardness, friability, and drug content met the required standards. In-vitro dissolution studies revealed variable drug release profiles among different formulations, attributed to the choice and concentration of osmotic agents. The F-02 formulation, containing Mannitol and Fructose, demonstrated extended drug release over 12 hours.
Results- in the Kinetic analysis of drug release indicated that most formulations followed zero-order kinetics, with an Anomalous non-Fickian diffusion mechanism. This suggests that the release of Glipizide from OCR tablets is not solely governed by Fickian diffusion but is also influenced by other mechanisms.
Conclusion: The development of Glipizide OCR tablets offers a promising approach to improve drug delivery, reduce dosing frequency, and enhance patient compliance in treating diabetes.
Keywords: Osmotic controlled-release (OCR), Glipizide, Oral drug delivery, Zero-order kinetics, Anomalous diffusion, Excipients
Keywords:
Osmotic controlled-release (OCR), Glipizide, Oral drug delivery, Zero-order kinetics, ExcipientsDOI
https://doi.org/10.22270/jddt.v16i7.7859References
[1] S.U W, Mishra A, S.G K. Recent Advances in Polymeric Microparticles - Based Drug Delivery Systems for the Treatment of Diabetes. RJPT 2025:1611–8. https://doi.org/10.52711/0974-360X.2025.00231.
[2] Mishra A, Waghamare S, Khanage SG. Acarbose-Loaded PLGA Microspheres: Efficient Encapsulation and Controlled Release. J Drug Delivery Ther 2025;15:30–40. https://doi.org/10.22270/jddt.v15i6.7165.
[3] Suresh W, Salpure S, Nikam M. The Gut Microbiome and Diabetes: A Review of Current Understanding and Therapeutic Implications. RJPPD 2025:295–303. https://doi.org/10.52711/2321-5836.2025.00046.
[4] Sahin I, Bakiner O, Demir T, Sari R, Atmaca A. Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review. Diabetes Ther 2024;15:1687–716. https://doi.org/10.1007/s13300-024-01612-8.
[5] Nokhodchi A, Raja S, Patel P, Asare-Addo K. The Role of Oral Controlled Release Matrix Tablets in Drug Delivery Systems. BioImpacts; ISSN 2228-5660 2012. https://doi.org/10.5681/BI.2012.027.
[6] Almoshari Y. Osmotic Pump Drug Delivery Systems—A Comprehensive Review. Pharmaceuticals 2022;15:1430. https://doi.org/10.3390/ph15111430.
[7] Keraliya RA, Patel C, Patel P, Keraliya V, Soni TG, Patel RC, et al. Osmotic Drug Delivery System as a Part of Modified Release Dosage Form. ISRN Pharmaceutics 2012;2012:1–9. https://doi.org/10.5402/2012/528079.
[8] Navarro-Tumar D, García-Merino B, González-Fernández C, Ortiz I, San-Román Ma-F, Bringas E. Novel Applications in Controlled Drug Delivery Systems by Integrating Osmotic Pumps and Magnetic Nanoparticles. Sensors 2024;24:7042. https://doi.org/10.3390/s24217042.
[9] Abd-Elbary A, Tadros MI, Alaa-Eldin AA. Development and In Vitro/In Vivo Evaluation of Etodolac Controlled Porosity Osmotic Pump Tablets. AAPS PharmSciTech 2011;12:485–95. https://doi.org/10.1208/s12249-011-9608-z.
[10] Shelke PS, U W, Rk S, Pawar TB, Bhingar HR, Narode PA. A review on solubility enhancement technique. Int J Pharm Pharm Sci 2024;6:144–8. https://doi.org/10.33545/26647222.2024.v6.i1b.113.
[11] Shrivastava A, Sharma S, Kaurav M, Sharma A. CHARACTERISTICS AND ANALYTICAL METHODS OF MANNITOL: AN UPDATE. Int J App Pharm 2021:20–32. https://doi.org/10.22159/ijap.2021v13i5.42068.
[12] Panda RR, Tiwary AK. Formulation and Optimization of Osmotically Controlled Release Tablets of Glipizide: Hot Melt Granulation. Therapeutic Delivery 2010;1:763–74. https://doi.org/10.4155/tde.10.71.
[13] I MR, Damodharan N. Mathematical Modelling of Dissolution Kinetics in Dosage forms. Rese Jour of Pharm and Technol 2020;13:1339. https://doi.org/10.5958/0974-360X.2020.00247.4.
[14] Jamzad S, Fassihi R. Development of a controlled release low dose class II drug-Glipizide. International Journal of Pharmaceutics 2006;312:24–32. https://doi.org/10.1016/j.ijpharm.2005.12.037.
[15] Kumar YS, Patel P, Ch S, B R. Formulation and Evaluation of Taste Masked Oral Disintegrating Tablets of Aripiprazole. PCI- Approved-IJPSN 2015;8:2723–34. https://doi.org/10.37285/ijpsn.2015.8.1.4.
[16] United States Pharmacopoeia. United States Pharmacopoeia Convention; 2008.
[17] Gupta SK, Patra S. Development, Characterization and Pharmacokinetic Evaluation of Optimized Vildagliptin Sustained Release Matrix Tablet Using Box-Behnken Design. Int J App Pharm 2024:214–33. https://doi.org/10.22159/ijap.2024v16i1.48052.
[18] Madrid MA, Fuentes JM, Ayuga F, Gallego E. Determination of the Angle of Repose and Coefficient of Rolling Friction for Wood Pellets. Agronomy 2022;12:424. https://doi.org/10.3390/agronomy12020424.
[19] Shah DS, Moravkar KK, Jha DK, Lonkar V, Amin PD, Chalikwar SS. A concise summary of powder processing methodologies for flow enhancement. Heliyon 2023;9:e16498. https://doi.org/10.1016/j.heliyon.2023.e16498.
[20] Moravkar KK, Korde SD, Bhairav BA, Shinde SB, Kakulade SV, Chalikwar SS. Traditional and Advanced Flow Characterization Techniques: A Platform Review for Development of Solid Dosage Form. Ijps 2020;82. https://doi.org/10.36468/pharmaceutical-sciences.726.
[21] Indian Pharmacopoeia. Ghaziabad: The Indian Pharmacopoeia Commission; 2007.
[22] Salawi A. Pharmaceutical Coating and Its Different Approaches, a Review. Polymers 2022;14:3318. https://doi.org/10.3390/polym14163318.
[23] Jacques ER, Alexandridis P. Tablet Scoring: Current Practice, Fundamentals, and Knowledge Gaps. Applied Sciences 2019;9:3066. https://doi.org/10.3390/app9153066.
[24] Alotaibi BS, Khan MA, Ullah K, Yasin H, Mannan A, Khan SA, et al. Formulation and characterization of glipizide solid dosage form with enhanced solubility. PLoS ONE 2024;19:e0297467. https://doi.org/10.1371/journal.pone.0297467.
[25] Shoaib MH, Tazeen J, Merchant HA, Yousuf RI. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC. Pak J Pharm Sci 2006;19:119–24.
[26] Trenfield SJ, Basit AW. Modified drug release: Current strategies and novel technologies for oral drug delivery. Nanotechnology for Oral Drug Delivery, Elsevier; 2020, p. 177–97. https://doi.org/10.1016/B978-0-12-818038-9.00006-5.
[27] Higuchi T. Mechanism of sustained‐action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. Journal of Pharmaceutical Sciences 1963;52:1145–9. https://doi.org/10.1002/jps.2600521210.
[28] Bayer IS. Controlled Drug Release from Nanoengineered Polysaccharides. Pharmaceutics 2023;15:1364. https://doi.org/10.3390/pharmaceutics15051364.
[29] Mathematical models of drug release. Strategies to Modify the Drug Release from Pharmaceutical Systems, Elsevier; 2015, p. 63–86. https://doi.org/10.1016/B978-0-08-100092-2.00005-9.
[30] Ekenna IC, Abali SO. Comparison of the Use of Kinetic Model Plots and DD Solver Software to Evaluate the Drug Release from Griseofulvin Tablets. J Drug Delivery Ther 2022;12:5–13. https://doi.org/10.22270/jddt.v12i2-S.5402.
[31] England CG, Miller MC, Kuttan A, Trent JO, Frieboes HB. Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2015;92:120–9. https://doi.org/10.1016/j.ejpb.2015.02.017.
[32] Dasari N, Chandra Padala R, Muvva S. Formulation and In vitro Evaluation of Acrivastine Controlled Release Tablets. AJPT 2023:95–100. https://doi.org/10.52711/2231-5713.2023.00018.
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Suresh Waghamare , Shaikh Nadera Tamkeen Saeeduzzafar , Tejas Ghuge , Dinesh Thore
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.